PGR and inflammatory breast carcinoma: The molecular subtypes of IBC patients include hormone receptor-positive (HR+, positive for estrogen and/or progesterone receptors)/HER2+ (14.8%), HR+/HER2-negative (HER2−; 35.7%), HR−/HER2+ (23.1%), and triple-negative (TN-IBC, negative for estrogen and progesterone receptors and HER2; 26.4%) [7].